Despite the rapid development of new agents, myeloma (MM) continues to be an incurable disease. Growing bodies of literature suggest a key role of natural killer (NK) cells, a unique subset of CD3 −
CD56
+ innate lymphoid cells in the control of newly diagnosed MM. 1 MM cells promote a state of progressive immune dysregulation and suppression of NK cell functions, which support a growing interest for NK cell-based immunotherapy. 2 A major challenge to the broader application of adoptive NK cell therapy is to improve methods for in vitro expansion of low-frequency NK cells. Large-scale expansions have been obtained with various feeder cell-based systems but whereas these methods have merit, they also have major drawbacks including complicated procedures, safety issues for human administration and/or the expansion of exhausted NK cells. 3 Developing innovative strategies to generate clinically efficient NK cells with minimal in vitro manipulation, in large numbers, would provide an important breakthrough in NK cell-based immunotherapy. In the present studies, we report a strategy designed specifically for MM through expansion with polyvalent immunoglobulins (polyIgs) and platelet lysate (PL) in the presence of lenalidomide.
NK cells were isolated from the non-mobilized apheresis product of 15 healthy donors who had given informed consent. The apheresis product started with 8.1 ± 4.4% NK cells. After depletion of CD3 + T cells and enrichment of CD56 + NK cells using the MACS selection system with CD3 and CD56 microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), the mean frequency of CD3 − CD56 + NK cells was 94.6 ± 1.9%, yielding an NK cell recovery of 35% with a mean T-cell depletion of 2.99 log.
Freshly isolated CD3 − CD56 + cells were cultured in 24-well plates (Thermo Scientific Nunc A/S, Roskilde, Denmark) at a concentration of 0.5x10 6 cells/mL, in CellGro SCGM Medium good manufacturing practice (Cellgenix, Freiburg, Germany) containing 10 μg/mL ciprofloxacine (Bayer Santé, Puteaux, France) and 5 IU/ mL Fragmine (Pfizer, Paris, France). It was previously suggested that IL-2 predisposed NK cells to the activation of induced cell death, whereas IL-15 promoted NK cell development and survival. 4 In the present study, a median of 7.1 ± 0.7-fold NK cell expansion was obtained with IL-15 (Miltenyi Biotec, Bergisch Gladbach, Germany; 10 ng/mL) alone. In combination with IL-2 (Proleukin, Novartis Pharma, Rueil-Malmaison, France), NK cell growth increased significantly in a dose-dependent manner from 24.6 ± 2.5 (at 100 IU/mL) to 55.5 ± 6.0-fold (at 600 IU/mL) (P = 0.017) (Figure 1a, upper panel) . Subsequently, cultures were performed in the presence of IL-15 (10 ng/mL) and IL-2 (600 IU/mL).
Concomitantly, we tested NK cell expansion through coating. It has been suggested that anti-CD3 can potentiate the proliferation of NK cells through an indirect effect on T cells 2 or alternatively, we postulate the association of the Fc fragment with FcgRIII CD16, mainly expressed on mature NK cells. To test this hypothesis, we used human polyclonal immunoglobulins (PolyIgs; Tégéline, LFB Biomédicaments, Les Ulis, France) in place of good manufacturing practice anti-CD3 mAb (Miltenyi). 5 We also evaluated the replacement of human ABs by human plateletderived growth factor that is allowed for the good manufacturing practice-compliant implementation of various clinical trials using mesenchymal stromal cells, but without evidence of its influence on immunomodulatory cells. 6 The cells were stimulated by surface immobilized anti-CD3 mAb (5 μg/mL) or surface immobilized human polyIgs (50 mg/mL) in the presence of 5% heat-inactivated ABs (EFS) or 8% PL (Macopharma, Tourcoing, France) for 7 days; cultures were extended for a second week using similar conditions except coating. Coating with anti-CD3 mAb or PolyIgs increased expansion of NK cells to, respectively, 72.1 ± 38.5 and 80.2 ± 20.5-fold compared with expansion without coating (7.5 ± 0.5-fold increase). Overall, in these cultures of NK cells, PL and polyvalent Ig could replace 'Gold standard' ABs and anti-CD3 with similar NK cells expansion ( Figure 1a , middle and bottom panels).
In these different culture conditions, NK cells were viable, highly activated (CD69, NKp46 and NKp44) ( Figure 1c ) and expressed activating (NKp30 and NKG2D) and chemokine receptors (data not shown), previously described to participate in the regulation of NK cell trafficking in vivo. 7 Of note, the percentage of contaminating CD3 + T cells remained stable (data not shown). We and others previously reported no significant change of inhibitory KIR receptors in expanded NK cells from healthy individuals. 8 We next assessed the functional capacities of expanded NK cells in six independent experiments using a standard 4-h 51 Cr-release assay and a polyfunctionality assay with simultaneously detection of degranulation (anti-CD107a mAb, H4A3; BD Biosciences, Le Pont de Claix, France) and cytokine production (intracellular expression IFN-γ (B27; BD Biosciences) and TNF-α (E-Biosciences, Paris, France). In four different conditions: anti-CD3 mAb+5% ABs, anti-CD3 mAb+8% PL, polyIgs+5% ABs or PolyIgs+8% PL, there was a trend to increased-specific lysis after expansion with polyIgs compared with anti-CD3 mAb ( Figure 2a ). This lytic activity with polyIgs is in agreement with previous results reported in Kawasaki disease, CMV and EBV infection in which IVIG contribute to both expansion and activity of circulating CD16 + mature NK cells. 10 A significant elevation of the degranulation capacities was also observed in the presence of PL (P = 0.03) (Figure 1d, lower panel) . These data are in accordance with the interaction between NK cells and platelets. Although the knowledge about their crosstalk is still fragmentary, storage granules in platelets contain proteins involved in cell proliferation as well as several immune modulators and chemokines (that is, neutrophilactivating peptide 2, PF4, CCL-3, CCL-5 or CCL-7) that control activation of NK cells and regulate their motility and chemotactism. 
+ cultured in the presence of 10 ng/mL IL-15+600 IU/mL IL-2 and 5% human ABs were tested without coating (square) or after coating with anti-CD3 mAb (triangle) or polyIg (circle). Bottom panel: effect of PL. Purified CD3 − CD56 + cultured in the presence of 10 ng/mL IL-15+600 IU/mL IL-2 and coated with polyIg were tested in the presence of 5% ABs (square) or 8% PL (triangle), and compared with untreated cells (circle). NS: non significant. The role of NK cells in MM provided a rationale for testing the functional activity of expanded NK cells against myeloma cells.
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In the presence of purified primary CD138 + myeloma cell subset, from patients at diagnosis or in relapse, we observed a robust increase of the specific cytotoxicity in the presence of PL compared with ABs, whatever the E:T ratio in accordance with data observed with K562 target cells. This effect was reproducibly observed and statistically significant in four experiments (Wilcoxon test; P = 0.035) (Figure 2a) . Of note, 51 Cr-release assay is complex against CD138 + primary myeloma cells with low level of cytotoxicity. 13 In addition, in the presence of the purified CD138 − cells from MM patients, we observed that NK cells were also more efficient in the presence of PL (Figure 2a) . Together, this suggested that PL amplified cytotoxicity against different target cells, including CD138
+ myeloma tumor cells. There is growing evidence that lenalidomide, an immunomodulatory drug active against myeloma, also modulates the cellular immune system, particularly NK cells 14 and this prompted us to test its influence on functional activity of expanded NK cells against myeloma cells. To access the effect of lenalidomide on cytotoxicity, NK cells were maintained in culture with lenalidomide at 5 or 50 μM during the last 48-h period of culture, to avoid toxic effect generated by a more long-term culture. In the presence of polyIgs and PL, lenalidomide increased both cytotoxicity and polyfunctional activity against primary CD138 + myeloma cells, and this effect was enhanced in the presence of PL, compared with ABs (P = 0.0218). (Figure 2c ) in dose-response manner (5 vs 50 μM; data non shown). Interestingly, using Wilconson test, lnalidomide significantly increased lysis of K562 target cells (P = 0.008) and the frequency of polyfunctional NK cells (P = 0.0136) and decreased the frequency of non-functional NK cells (P = 0.03) in seven experiments performed with K562 target cells (Figure 2b ). Taken together, the expansion of polyfunctional NK cells against target cells, including CD138 + myeloma cells from MM patients, could be enhanced by lenalidomide via a putative early apoptotic NK cells rescuing effect. In contrast with previous studies suggesting an effect of NK cells towards T cells, 15 our findings show a direct effect of lenalidomide on expanded NK cells.
In conclusion, we developed a novel and safe strategy requiring only minimal in vitro manipulation, which includes polyIgs, PL and lenalidomide to generate large number of functional NK cells. This approach is now being upgraded to complete good manufacturing practice conditions for a clinical trial of adoptive transfer of alloreactive polyfunctional NK cells specifically designed to fight myeloma tumor cells.
